Acadia drug approval could clear way for Axovant dementia therapy
April 28, 2016 at 12:59 PM EDT
April 28 (Reuters) - An imminent ruling on Acadia Pharmaceuticals Inc's drug for Parkinson's disease psychosis is being closely watched by a Bermuda-based company with a similar treatment for dementia.